Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

Colorectal Neoplasms Clinical Trial

Official title:

Efficacy and Safety of Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer: a Single-center, Retrospective, Controlled Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06024356
• Other study ID #: BFH-TTNCRT
• Status: Not yet recruiting
• Start date: September 20, 2023
• Est. completion date: March 30, 2024

Study information

• Verified date: September 2023
• Source: Beijing Friendship Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

It is a single-center, retrospective, controlled study to investigate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.

Description:

Study Purpose

1. To evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin for locally advanced mid-low rectal cancer.

2. To explore the effects of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin on the immune microenvironment of locally advanced mid-low rectal cancer.

Study Design: A single-center, retrospective, controlled study Subjects were divided into two groups according to whether or not they received thymalfasin: group 1 was treated with neoadjuvant chemoradiotherapy combined with PD-1 inhibitor, and group 2 was treated with neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin.

Subjects received long course radiotherapy (50 Gy/25f, 2 Gy/f, 5 days/week) for the first 5 weeks and three 21-day cycles capecitabine (1000 mg/m2, bid, po, day1-14) plus three 21-day cycles tislelizumab (200 mg, iv.gtt, day 8) for the first 9 weeks. After that, patients rested for two weeks (week 10-11)。6-8 weeks after the end of radiotherapy, patients underwent TME surgery (12-14 weeks). Thymalfasin was started on the first day of neoadjuvant chemoradiotherapy, 1.6 mg subcutaneously twice a week until the end of the last neoadjuvant treatment.

Enrollment: 26 participants, 13 in each group Study Population: locally advanced mid-low rectal cancer Primary Endpoint: pathologic complete response（pCR） Exploratory endpoint: Paraffin specimens were collected from biopsies before neoadjuvant therapy and after surgery in patients meeting the inclusion criteria. The expression of CD86, CD163, CD4+T，CD8+T，PD-1 were detected.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 26
• Est. completion date: March 30, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with rectal adenocarcinoma must satisfied all the following conditions:

1. Stage II/III LARC (cT1-4aN0-2M0);

2. Tumor distal location=10 cm from anal verge (MRI diagnosed);

• Patients regardless of gender with aged=18 years

• ECOG score of 0 or 1

• Physical and viscera function of patients can withstand major abdominal surgery

Exclusion Criteria:

• Current or previous active malignancy other than rectal cancer;

• Patients underwent major surgery within 4 weeks prior to neoadjuvant therapy;

• Patients have any condition affects the absorption of capecitabine through gastrointestinal tract;

• Patients have severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases;

• Patients with severe concomitant diseases with estimated survival=5 years;

• Patients with present or previous moderate or severe liver and kidney damage;

• Patients preparing for or previously received organ or bone marrow transplant;

• Patients who have received immunosuppressive or systemic hormone therapy within 1 month prior to the start of neoadjuvant therapy;

• Patients with congenital or acquired immune deficiency (such as HIV infection);

• Pregnant or lactating women.

Related Conditions & MeSH terms

• Colorectal Neoplasms

Intervention

Drug:
• Thymalfasin
Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. It has been evaluated for its immunomodulatory activities and related therapeutic potential in several diseases.

Locations

Country	Name	City	State
China	Beijing Friendship Hospital, Capital medical University	Beijing	Xicheng Dis

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The expression of CD86	The density, H-score of each marker in paraffin-embedded tissue sections detected by mIHC	1 year
Other	The expression of CD163	The density, H-score of each marker in paraffin-embedded tissue sections detected by mIHC	1 year
Other	The expression of CD4+	The density, H-score of each marker in paraffin-embedded tissue sections detected by mIHC	1 year
Other	The expression of CD8+	The density, H-score of each marker in paraffin-embedded tissue sections detected by mIHC	1 year
Other	The expression of PD-1	The density, H-score of each marker in paraffin-embedded tissue sections detected by mIHC	1 year
Primary	pathologic complete response	All the enrolled patients will receive total mesorectal excision (TME) 7-9 weeks after the end of long course radiotherapy. The rectal specimens will be evaluated by the pathologists who are experienced on the rectal cancer diagnosis according to the 1997 Dworak grading system. The rectal cancer will be classified into 5 grades. Grade 0-3 will be considered as non-pCR while grade 4 represent pCR.	1 year
Secondary	neoadjuvant rectal (NAR) score	The neoadjuvant rectal (NAR) score is a promising indicator of survival after preoperative chemoradiotherapy for rectal cancer. The NAR score was calculated according to the following formula: NAR score = [5pN - 3(cT - pT) + 12]2/9.61.; (clinical tumor (cT) stage, pathologic tumor (pT) stage, pathologic nodal (pN) stage)	1 year
Secondary	tumor regression grade(TRG)	AJCC 8th TRG classification. TRG 0: No viable cancer cells left in the specimen; complete regression.; TRG 1: Minimal residual cancer cells present; extensive regression with a minimal number of tumor cells.; TRG 2: Moderate residual cancer cells present; substantial regression with a significant number of tumor cells.; TRG 3: Minimal or no regression; no significant tumor cell response to treatment; majority of tumor still present.	1 year
Secondary	objective response rate (ORR)	ORR is evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The ORR rate is the sum of complete response (CR) and partial response (PR)	1 year
Secondary	R0 resection rate	During the surgical process, the surgeon will evaluate the level of cancer resection. It will be classified as R0, R1, R2 resection. Therefore, we can calculate R0 resection rate.	1 year
Secondary	anal preservation rate	the surgeon will decide whether the anal can be preserved on the basis of the rectal cancer and intraoperative situation. anal preservation rate is the percentage of patients who achieve anal preservation.	1 year
Secondary	disease free survival (DFS)	During the 3-year follow-up, the percentage of the patients who is disease free.	3 year
Secondary	local recurrence free survival	During the 3-year follow-up, the percentage of local recurrence.	3 year
Secondary	overall survival (OS)	During the 3-year follow-up, the percentage of the patients who is sill survival at the end of follow-up.	3 year